サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1546243

リアルワールド・エビデンス・ソリューションの世界市場

Real World Evidence Solutions

出版日
ページ情報
英文 246 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
リアルワールド・エビデンス・ソリューションの世界市場
出版日: 2024年09月03日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 246 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

リアルワールド・エビデンス・ソリューションの世界市場は2030年までに44億米ドルに達する見込み

2023年に17億米ドルと推定されるリアルワールド・エビデンス・ソリューションの世界市場は、2023年から2030年にかけてCAGR 14.3%で成長し、2030年には44億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるリアルワールドエビデンスサービスは、CAGR 15.5%を記録し、分析期間終了時には29億米ドルに達すると予測されます。実世界証拠データセット分野の成長率は、分析期間中CAGR 12.1%と推定されます。

米国市場は4億6,090万米ドルと推定、中国はCAGR13.3％で成長予測

米国のリアルワールド・エビデンス・ソリューション市場は、2023年に4億6,090万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに6億5,260万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは13.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、それぞれ分析期間中に12.9%と12.0%のCAGRで成長すると予測されています。欧州では、ドイツがCAGR 10.1%で成長すると予測されています。

世界のリアルワールド・エビデンス・ソリューション市場- 主要動向と促進要因まとめ

リアルワールド・エビデンス・ソリューション：データ駆動型インサイトによるヘルスケアの変革

リアルワールドエビデンス（RWE）ソリューションは、業界全体の意思決定を強化するデータ主導型の洞察を提供することで、ヘルスケアを変革しています。RWEとは、実世界データ（RWD）の分析から導き出される、医薬品の使用法や潜在的なベネフィットまたはリスクに関する臨床エビデンスのことです。このデータは、電子カルテ（EHR）、請求データベース、患者登録、ウェアラブルデバイスなど、さまざまな情報源から収集されます。RWEは、製薬会社、規制当局、ヘルスケアプロバイダーによって、医薬品開発、規制当局の承認、患者のケア戦略に情報を提供するために利用されるようになってきています。管理された条件下で実施される従来の臨床試験とは異なり、RWEは日常的な臨床現場で治療がどのように行われるかについての洞察を提供し、製品の有効性と安全性をより包括的に理解します。このアプローチは、特に個別化医療や希少疾患において、新しい治療法の価値を実証するために不可欠なものとなっています。

どのような技術の進歩がRWEの収集と活用を強化しているのか？

技術の進歩により、RWEの収集、分析、活用が大幅に強化され、ヘルスケア関係者にとってより強力なツールとなっています。ビッグデータ分析、人工知能（AI）、機械学習（ML）をRWEプラットフォームに統合することで、膨大な量のRWDを処理し、手作業では検出不可能なパターンや洞察を明らかにすることができます。また、データ統合技術の進歩により、多様なソースからのデータの集約が可能になり、患者の転帰を全体的に把握できる包括的なデータセットが作成されています。さらに、自然言語処理（NLP）の利用により、医師のメモやソーシャルメディアなどの非構造化ソースからの意味のあるデータの抽出が改善されつつあります。これらの技術革新は、RWEの品質と精度を向上させるだけでなく、ヘルスケアにおける意思決定者にとって、RWEをより利用しやすく、実用的なものにしています。

ヘルスケアにおけるRWEの主な用途と利点は？

RWEはヘルスケアにおける広範なアプリケーションで使用され、患者の転帰を向上させ、医療効率を改善し、規制上の意思決定をサポートする大きな利点を提供しています。医薬品開発では、RWEは臨床試験データを補完するために使用され、異なる集団や実世界の設定で薬がどのように機能するかについての洞察を提供し、ラベリングや市販後調査に情報を提供することができます。ヘルスケアプロバイダーは、特定の患者集団に最も効果的な治療を特定するためにRWEを使用し、個々のニーズに合わせて治療を行う個別化医療のアプローチをサポートします。支払者と保険会社は、RWEを活用して治療の費用対効果を評価し、償還決定を導き、最大の価値を提供する治療にリソースを確実に割り当てます。RWEの主な利点には、医療製品の実際の有効性と安全性に関する洞察を提供し、エビデンスに基づく意思決定を支援し、実際の患者の経験に基づく治療戦略を通知することによって患者の治療を改善する能力が含まれます。

リアルワールド・エビデンス・ソリューション市場の成長を促進する要因は？

リアルワールド・エビデンス・ソリューション市場の成長は、いくつかの要因によってもたらされます。ヘルスケアの利害関係者が確かなエビデンスに基づいて情報に基づいた意思決定を行おうとする中、価値観に基づく医療が重視されるようになり、医療製品の実際の有効性を実証する必要性が高まっていることが大きな促進要因となっています。データ分析、AI、デジタルヘルスプラットフォームの技術的進歩も、RWEソリューションの機能とアクセシビリティを高めることで市場の成長を促進しています。個別化医療に対する需要の高まりと、特に希少疾患や複雑な疾患に対する規制当局の承認をサポートするデータの必要性が、RWEの需要をさらに押し上げています。さらに、EHR、ウェアラブルデバイス、患者報告アウトカムの採用により、デジタルヘルスデータの利用可能性が高まっており、RWE調査範囲と規模が拡大しています。これらの要因は、製薬会社、ヘルスケアプロバイダー、規制機関の間の協力関係の増加と相まって、リアルワールド・エビデンス・ソリューション市場の持続的な成長を促進しています。

調査対象企業の例（注目の全46社）

  • Aetion
  • Cognizant Technology Solutions U.S. Corporation
  • IBM Corporation
  • Ignite Data Limited
  • IQVIA
  • PAREXEL International Corporation
  • PerkinElmer, Inc.
  • Pharmaceutical Product Development LLC
  • SAS Institute, Inc.
  • Syneos Health

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP14362

Global Real World Evidence Solutions Market to Reach US$4.4 Billion by 2030

The global market for Real World Evidence Solutions estimated at US$1.7 Billion in the year 2023, is expected to reach US$4.4 Billion by 2030, growing at a CAGR of 14.3% over the analysis period 2023-2030. Real World Evidence Services, one of the segments analyzed in the report, is expected to record a 15.5% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Real World Evidence Data Sets segment is estimated at 12.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$460.9 Million While China is Forecast to Grow at 13.3% CAGR

The Real World Evidence Solutions market in the U.S. is estimated at US$460.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$652.6 Million by the year 2030 trailing a CAGR of 13.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.9% and 12.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.1% CAGR.

Global Real World Evidence Solutions Market - Key Trends and Drivers Summarized

Real World Evidence Solutions: Transforming Healthcare with Data-Driven Insights

Real World Evidence (RWE) solutions are transforming healthcare by providing data-driven insights that enhance decision-making across the industry. RWE refers to the clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of real-world data (RWD). This data is collected from various sources, including electronic health records (EHRs), claims databases, patient registries, and wearable devices. RWE is increasingly being used by pharmaceutical companies, regulators, and healthcare providers to inform drug development, regulatory approvals, and patient care strategies. Unlike traditional clinical trials, which are conducted under controlled conditions, RWE provides insights into how treatments perform in everyday clinical settings, offering a more comprehensive understanding of a product’s effectiveness and safety. This approach is becoming essential for demonstrating the value of new therapies, especially in personalized medicine and for rare diseases.

What Technological Advancements Are Enhancing the Collection and Utilization of RWE?

Technological advancements are significantly enhancing the collection, analysis, and utilization of RWE, making it a more powerful tool for healthcare stakeholders. The integration of big data analytics, artificial intelligence (AI), and machine learning (ML) into RWE platforms allows for the processing of vast amounts of RWD, uncovering patterns and insights that would be impossible to detect manually. Advances in data integration technologies are also enabling the aggregation of data from diverse sources, creating comprehensive datasets that provide a holistic view of patient outcomes. Moreover, the use of natural language processing (NLP) is improving the extraction of meaningful data from unstructured sources, such as physician notes and social media. These technological innovations are not only improving the quality and accuracy of RWE but are also making it more accessible and actionable for decision-makers in healthcare.

What Are the Key Applications and Benefits of RWE in Healthcare?

RWE is used in a wide range of applications in healthcare, offering significant benefits that enhance patient outcomes, improve healthcare efficiency, and support regulatory decision-making. In drug development, RWE is used to supplement clinical trial data, providing insights into how a drug performs across different populations and in real-world settings, which can inform labeling and post-market surveillance. Healthcare providers use RWE to identify the most effective treatments for specific patient populations, supporting personalized medicine approaches that tailor care to individual needs. Payers and insurers leverage RWE to assess the cost-effectiveness of treatments, guiding reimbursement decisions and ensuring that resources are allocated to therapies that offer the greatest value. The primary benefits of RWE include its ability to provide insights into the real-world effectiveness and safety of medical products, support evidence-based decision-making, and improve patient care by informing treatment strategies based on actual patient experiences.

What Factors Are Driving the Growth in the Real World Evidence Solutions Market?

The growth in the Real World Evidence Solutions market is driven by several factors. The increasing emphasis on value-based care and the need to demonstrate the real-world effectiveness of medical products are significant drivers, as healthcare stakeholders seek to make informed decisions based on robust evidence. Technological advancements in data analytics, AI, and digital health platforms are also propelling market growth by enhancing the capabilities and accessibility of RWE solutions. The rising demand for personalized medicine and the need for data to support regulatory approvals, particularly for rare diseases and complex conditions, are further boosting demand for RWE. Additionally, the growing availability of digital health data, driven by the adoption of EHRs, wearable devices, and patient-reported outcomes, is expanding the scope and scale of RWE studies. These factors, combined with increasing collaboration between pharmaceutical companies, healthcare providers, and regulatory bodies, are driving the sustained growth of the Real World Evidence Solutions market.

Select Competitors (Total 46 Featured) -

  • Aetion
  • Cognizant Technology Solutions U.S. Corporation
  • IBM Corporation
  • Ignite Data Limited
  • IQVIA
  • PAREXEL International Corporation
  • PerkinElmer, Inc.
  • Pharmaceutical Product Development LLC
  • SAS Institute, Inc.
  • Syneos Health

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Real World Evidence Solutions - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Evidence-Based Healthcare Propels Market Growth
    • Technological Advancements in Data Integration and Analytics Strengthen Market Position
    • Growing Focus on Personalized Medicine and Patient-Centric Care Drives Adoption of Real World Evidence Solutions
    • Surge in Demand for Post-Market Surveillance and Safety Monitoring Generates New Opportunities
    • Development of Advanced Data Collection and Management Platforms Sustains Market Growth
    • Expanding Applications in Drug Development and Clinical Trials Throws Spotlight on Market Potential
    • Rising Adoption of Real World Evidence in Payer Decision-Making and Reimbursement Processes Propels Market Expansion
    • Surge in Demand for Real-Time Data and Predictive Analytics Expands Market Horizons
    • Growing Awareness of the Benefits of Real World Evidence in Enhancing Treatment Outcomes Drives Market Adoption
    • Innovations in Artificial Intelligence and Machine Learning Generate New Market Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Real World Evidence Solutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World 7-Year Perspective for Real World Evidence Solutions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Data Sets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 4: World 7-Year Perspective for Data Sets by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World 7-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Healthcare Payers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World 7-Year Perspective for Healthcare Payers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Healthcare Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 10: World 7-Year Perspective for Healthcare Providers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World 7-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 13: World Real World Evidence Solutions Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pharmaceutical & Medical Devices Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World 7-Year Perspective for Pharmaceutical & Medical Devices Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 16: USA Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 17: USA 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 18: USA Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 19: USA 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Canada 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 22: Canada Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 23: Canada 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • JAPAN
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 24: Japan Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 25: Japan 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Japan 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • CHINA
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 28: China Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 29: China 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 30: China Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 31: China 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • EUROPE
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Real World Evidence Solutions by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe 7-Year Perspective for Real World Evidence Solutions by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 34: Europe Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 35: Europe 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 36: Europe Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 37: Europe 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • FRANCE
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 38: France Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: France 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 40: France Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 41: France 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • GERMANY
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 42: Germany Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 43: Germany 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 44: Germany Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Germany 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • ITALY
    • TABLE 46: Italy Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Italy 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 48: Italy Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Italy 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • UNITED KINGDOM
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 50: UK Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: UK 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 52: UK Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 53: UK 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 54: Rest of Europe Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 55: Rest of Europe 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Rest of Europe 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 58: Asia-Pacific Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 59: Asia-Pacific 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 60: Asia-Pacific Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 61: Asia-Pacific 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 62: Rest of World Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Rest of World 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 64: Rest of World Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 65: Rest of World 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030

IV. COMPETITION